

Amendments to the Claims:

Please amend the claims as forth hereinafter.

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


1. (Previously Presented) A method for the preparation of *trans*- or *cis*-diammoniumdichlorodihydroxoplatinum(IV) or derivatives thereof.

wherein

trans- or *cis*-diammoniumdichloroplatinum(II) is reacted with a solution comprising >30% peroxide at temperatures below 30°C, and

the product obtained is dissolved in a mineral acid and subsequently precipitated with an alkaline solution.

2. (Currently Amended) A compound of general formula



wherein X₁, X₂ = calcium, magnesium, sodium, potassium, lithium ions, alkyl and/or aryl residues.

- ### 3. to 5. (canceled)

6. (Original) A pharmaceutical agent, comprising a compound according to claim 2, optionally
Appl. No. 10/595,400

together with a pharmaceutically tolerable carrier, adjuvant and/or vehicle.

7. (Previously Presented) The pharmaceutical agent according to claim 6, wherein the carriers are fillers, diluents, binders, humectants, disintegrants, dissolution retarders, absorption enhancers, wetting agents, adsorbents and/or lubricants.

8. (Previously Presented) The pharmaceutical agent according to claim 6, wherein the carriers are liposomes, siosomes and/or niosomes.

9. (Original) A kit comprising the compounds according to claim 2, optionally together with information for combining the contents of the kit.

10. (Canceled)

11. (Currently Amended) A method for prophylaxis, ~~therapy, follow-up and aftercare~~ of a disease associated with cell growth, cell differentiation and/or cell division comprising

administering the compound of claim 2 to a person in need of such prophylaxis, ~~therapy, follow-up or aftercare~~ for a disease associated with cell growth, cell differentiation and/or cell division in a prophylactically, ~~therapeutically, follow-up or aftercare~~ effective amount.

12. (Previously Presented) The method of claim 11, wherein said disease is a tumor.

13. (Previously Presented) The method of claim 11, wherein the compound is administered orally, vaginally, rectally, nasally, subcutaneously, intravenously, intramuscularly, intraperitoneally, regionally and/or topically.

14. (Previously Presented) The method of claim 12, wherein the compound is administered orally, vaginally, rectally, nasally, subcutaneously, intravenously, intramuscularly, intraperitoneally, regionally and/or topically.

15. (Previously Presented) A combination tumor therapy comprising

administering the compound of claim 2 to a person in need of such therapy in a therapeutically effective amount, and
subjecting said person to a second tumor treatment.

16. (Previously Presented) The combination therapy of claim 15, wherein said second tumor treatment is chemotherapy, a treatment with cytostatic agents and/or a radiotherapy.

17. (Cancelled)

18. (New) A method for therapy, follow-up and aftercare of a disease associated with cell growth, cell differentiation and/or cell division comprising

administering the compound of claim 2 to a person in need of such therapy, follow-up or aftercare for a disease associated with cell growth, cell differentiation and/or cell division in a therapeutically, follow-up or aftercare effective amount.

19. (New) The method of claim 11, wherein said disease is a tumor.

20. (New) The method of claim 11, wherein the compound is administered orally, vaginally, rectally, nasally, subcutaneously, intravenously, intramuscularly, intraperitoneally, regionally and/or topically.

21. (New) The method of claim 12, wherein the compound is administered orally, vaginally, rectally, nasally, subcutaneously, intravenously, intramuscularly, intraperitoneally, regionally and/or topically.